On April 4, 2022 Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, reported that members of Mustang’s management team will participate in the two-day Fortress Biotech ("Fortress") Virtual R&D Summit taking place on Tuesday, April 5, 2022 and Wednesday, April 6, 2022 (Press release, Mustang Bio, APR 4, 2022, View Source [SID1234611408]). The Summit will be hosted by the B. Riley Securities’ Healthcare Equity Research team and will feature multiple programs from Fortress’ diversified pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mustang will present a corporate overview and participate in a panel discussion on Wednesday, April 6, 2022 at 1:30 p.m. ET. Registration for the event is available here.

Following the meeting, the webcast will be available on the on the News & Events page of the Investor Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days after the meeting.

On April 4, 2022 Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), reported the formation of a Joint Venture ("JV") with Dragon Overseas Capital Limited ("Dragon Overseas") (Press release, Oncotelic, APR 4, 2022, View Source [SID1234611407]). Dragon Overseas is a company affiliated with Golden Mountain Partners, LLC.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am excited to announce that, together with our partner Dragon Overseas, we have formed a JV for the discovery, development and commercialization of TGF-β therapeutics against all pharmaceutical indications," said Dr. Vuong Trieu, CEO and Chairman of Oncotelic. "This JV unburdens the Company of the high cost of drug development, which the JV will be responsible for, while the Company will participate in its upside through appreciation in the value of its shares in the JV."

Oncotelic to receive up to $50 million on sale of the RPD voucher following marketing approval of OT-101 for DIPG
Dragon Overseas has agreed to invest cash and other assets with a value of approximately $27.6 million for 55% ownership of the JV
Oncotelic has Licensed OT-101 to the JV for a 45% ownership in the JV
The Joint Venture to be headquartered in Hong Kong
Initial focus on the further development and commercialization of OT-101, including for DIPG as well as pancreatic cancers and glioblastoma
About OT-101

OT-101 has completed seven clinical trials including one phase 2 trial in COVID and two phase 2 trials in brain cancer and against pancreatic cancer. It has pediatric designation for a rare form of pediatric brain cancer known as DIPG. There are about 200-300 new cases of DIPG every year in the United States. DIPG most often occurs in children aged 5-10 years old. Treatment options are limited with surgery being contraindicated. Most children do not survive more than 2 years after diagnosis. Currently, the main treatment for DIPG is radiation therapy. Although radiation temporarily improves symptoms in most patients, it is not a cure. Palliative care or quality of life services help patients and families manage pain and other symptoms, promote quality of life, and making difficult decisions including treatment choices and end of life care.

When COVID-19 emerged in China, Oncotelic and GMP entered into a research and services agreement in February 2020 to develop and test COVID-19 antisense therapeutics. In March 2020, Oncotelic reported the anti-viral activity of OT-101. The anti-viral activity of OT-101, in an in vitro antiviral testing performed by an independent laboratory, OT-101 has a 50% effective concentration (EC50) of 7.6 µg/mL and is not toxic at the highest dose of 1000 µg/mL giving a safety index (SI) value of >130, which is considered highly active and on par or superior to Remdesivir – a Gilead drug. Unlike Remdesivir, OT-101 targets not only the virus replication but also the virus induced pneumonia and fibrosis. Our Phase 2 trial was completed for OT-101 in South America. This was a randomized, double-blind, placebo-controlled Phase 2 study intended to evaluate the safety and efficacy of OT-101 in adult patients hospitalized with positive SARS-CoV-2 and pneumonia. As reported in November 2021, the top line data was positive for safety and efficacy.

On April 4, 2022 Jeremy BASTID, CEO of OREGA Biotech, reported that it will participate to the upcoming AACR (Free AACR Whitepaper) annual meeting to be held on April 9-13 in New Orleans, Louisiana (Presentation, OREGA BIOTECH, APR 4, 2022, View Source [SID1234611406]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On April 4, 2022 Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, reported details for a planned investor webinar to coincide with the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place April 8-13 (Press release, Genocea Biosciences, APR 4, 2022, View Source [SID1234611405]). The presentation, beginning at 4:30 PM EDT on Friday, April 8th will be followed by a Q&A session. The Genocea team will discuss previously announced AACR (Free AACR Whitepaper) presentations, including late-breaking data from the TiTAN clinical trial for the neoantigen-targeted peripheral T cell therapy product candidate GEN-011, and results demonstrating successful production of GEN-011 using Genocea’s PLANET manufacturing process.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Featured speakers include:

Melissa Johnson, MD, Medical Oncologist at Sarah Cannon Research Institute at Tennessee Oncology
Chip Clark, President & Chief Executive Officer, Genocea Biosciences
Tom Davis, MD, Chief Medical Officer, Genocea Biosciences
Jessica Flechtner, PhD, Chief Scientific Officer, Genocea Biosciences
Ray Stapleton, PhD, Chief Technology Officer, Genocea Biosciences
Attendees can register HERE for the event. Access to the webcast will be available on the investor relations section of Genocea’s website, including an archived replay of the webcast at View Source

About GEN-011
GEN-011 is a neoantigen-targeted peripherally derived T cell therapy candidate comprised of autologous CD4+ and CD8+ T cells that are specific for up to 30 ATLAS-identified neoantigens to limit tumor escape. NPTs have minimal bystander, non-tumor-specific cells, and are devoid of Inhibigen-specific cells which may be detrimental to clinical response.

About the GEN-011 TiTAN clinical trial
TiTAN is an open-label, multi-center Phase1/2a trial evaluating safety, tolerability, T cell persistence and proliferation and clinical efficacy. The TiTAN clinical trial is testing two dosing regimens, a repeated fractional dose regimen of GEN-011 without lymphodepletion and a single dose administration of GEN-011 after lymphodepletion. Both groups will receive interleukin-2 after GEN-011 dosing to maximize the tumor-killing potential of the infused cells.

On April 4, 2022 Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, reported a publication in Nature Communications on the preclinical development of davoceticept, Alpine’s lead immuno-oncology therapeutic candidate uniquely designed to combine PD-L1-dependent CD28 costimulation with dual PD-L1 and CTLA-4 checkpoint inhibition (Press release, Alpine Immune Sciences, APR 4, 2022, View Source [SID1234611404]). CD28 is a critical T cell receptor recognized as a principal target of immune checkpoints like PD-1 and CTLA-4.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Lack of sufficient CD28 costimulation in the tumor microenvironment may underlie checkpoint inhibitor resistance and, therefore, CD28-directed treatments hold much promise. Davoceticept is an exciting first-in-class CD28-targeting drug that is distinct among others in this space for its triplicate mechanism and structural elegance," said Rafi Ahmed, PhD, Professor of Microbiology and Immunology and Vaccine Center Director at Emory University, and member of Alpine’s scientific advisory board.

"This achievement is the culmination of years of our scientists’ efforts to target CD28 in a highly differentiated fashion," remarked Stanford Peng, MD PhD, President and Head of R&D at Alpine. "It distinctively illustrates the unique yet powerful approach of our discovery platform, and further encourages us to continue to pursue clinical development of davoceticept with vigor."

Davoceticept is being studied in two clinical trials, NEON-1 as monotherapy, and NEON-2 in combination with pembrolizumab, in adults with advanced malignancies. Data from NEON-1 will be presented at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in New Orleans on April 12.

About Davoceticept (ALPN-202)

Davoceticept (ALPN-202) is a first-in-class, conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. Preclinical studies of davoceticept have successfully demonstrated superior efficacy in tumor models compared to checkpoint inhibition alone. Completion of dose escalation and initiation of expansion cohorts of NEON-1 (NCT04186637), a Phase 1 monotherapy dose escalation and expansion trial in patients with advanced malignancies, is anticipated in the first half of 2022. NEON-2 (NCT04920383), a combination study of davoceticept (ALPN-202) and pembrolizumab was initiated in June 2021 and is currently on partial clinical hold.